BlauveltA, LangleyRG, LacourJP, et al.Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic Dermatitis®: Interim analysis of the ECZTEND open-label extension trial. J Am Acad Dermatol, 2022; 87(4):815–824.
2.
SilverbergJI, TothD, BieberT, et al.Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic Dermatitis®: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial*. Br J Dermatol, 2021; 184(3):450–463.
3.
SilverbergJI, AdamDN, ZirwasM, et al.Tralokinumab plus topical corticosteroids as needed provides progressive and sustained efficacy in adults with moderate-to-severe atopic Dermatitis® over a 32-week period: An ECZTRA 3 post hoc analysis. Am J Clin Dermatol, 2022; 23(4):547–559.
